Skip to main content

Table 2 Incidence of adverse events occurring during study (starting after catheter insertion)

From: Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors

  Cohort 1 Cohort 2 Cohort 3 Cohort 4 Total
(n = 6) (n = 6) (n = 6) (n = 6) (N = 24)
Participants with one or more adverse event 6 (100.0) 6 (100.0) 3 (50.0) 4 (66.7) 19 (79.2)
 Headache 3 (50.0) 5 (83.3) 2 (33.3) 2 (33.3) 12 (50.0)
 Back pain 1 (16.7) 2 (33.3) 1 (16.7) 3 (50.0) 7 (29.2)
 Catheter site pain 2 (33.3) 0 1 (16.7) 0 3 (12.5)
 Dizziness postural 0 1 (16.7) 0 1 (16.7) 2 (8.3)
 Hypoesthesia 1 (16.7) 0 1 (16.7) 0 2 (8.3)
 Pain in extremity 1 (16.7) 0 1 (16.7) 0 2 (8.3)
 Nausea 0 1 (16.7) 1 (16.7) 0 2 (8.3)
 Musculoskeletal stiffness 0 1 (16.7) 0 0 1 (4.2)
 Neck pain 0 0 1 (16.7) 0 1 (4.2)
 Gastroesophageal reflux disease 0 0 1 (16.7) 0 1 (4.2)
 Regurgitation 0 0 0 1 (16.7) 1 (4.2)
 Toothache 0 0 0 1 (16.7) 1 (4.2)
 Dermatophytosis 0 0 1 (16.7) 0 1 (4.2)
 Sinusitis 0 0 0 1 (16.7) 1 (4.2)
 Post lumbar puncture syndrome 0 1 (16.7) 0 0 1 (4.2)
 Pruritus 1 (16.7) 0 0 0 1 (4.2)
 Flushing 0 1 (16.7) 0 0 1 (4.2)
  1. Data shown as n (%). Cohort 1: immediate sampling, high frequency; cohort 2: delayed sampling, high frequency, procedure effect; cohort 3: ibuprofen, high frequency, inflammation effect; cohort 4: immediate sampling, low frequency
  2. The laboratory parameters (clinical chemistry, hematology, urinalysis) were evaluated at screening, on days –1 and 2, and during follow-up (days 7–14 after removal of the spinal catheter). The vital signs and resting 12-lead ECGs were evaluated at screening, on days –1, 1, and 2, and during follow-up. The participants were physically and neurologically examined at screening, on days 1 and 3, and in follow-up. Fundoscopy was performed at screening to exclude intracranial pressure